Data showed that patients who had pathologic complete response in the neoadjuvant setting after treatment with a regimen containing Genetech's Perjeta experienced better progression-free and disease-free survival.
Researchers and commercial vendors highlighted new data and clinical utility, but also discussed challenges in validating and establishing liquid biopsy diagnostics.
Through targeted sequencing on tumors from several biliary tract subtypes, researchers are uncovering mutations of potential treatment or prognostic relevance.
Teams tracked immune cell infiltration, PD-L1 expression, and more in tumors from BRCA1/2-mutated ovarian cancers or mutation-rich endometrial cancer subtypes.
In the study, called TAPUR, ASCO will give cancer patients who are out of treatment options off-label drugs based on their genomic data and record their outcomes in a registry.
A genomics researcher from North Carolina State University outlined efforts to learn more about human cancers by studying dogs and other animals with spontaneous malignancies.
The proposed plan could better support doctors' ability to deliver precision cancer care by providing payment for services such as coordinating with pathologists and ordering the right test.
Researchers explored the predictive value of using mismatch repair deficiency and PD-L1 expression to assess which cancer patients are likely to respond to anti-PD-1 treatments.
The anti-PD-L1 drug significantly extended survival in NSCLC patients with high PD-L1 expression compared to docetaxel, while alectinib shrank tumors for those with ALK-positive tumors and brain metastases.
